ORGENESIS INC (ORGS) Fundamental Analysis & Valuation

NASDAQ:ORGSUS68619K2042

Current stock price

2.11 USD
-1.13 (-34.84%)
At close:
2.25 USD
+0.14 (+6.64%)
After Hours:

This ORGS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. ORGS Profitability Analysis

1.1 Basic Checks

  • ORGS had negative earnings in the past year.
  • ORGS had a negative operating cash flow in the past year.
  • In the past 5 years ORGS reported 4 times negative net income.
  • In the past 5 years ORGS always reported negative operating cash flow.
ORGS Yearly Net Income VS EBIT VS OCF VS FCFORGS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 -20M -40M -60M -80M

1.2 Ratios

  • ORGS has a Return On Assets of -124.09%. This is amonst the worse of the industry: ORGS underperforms 81.71% of its industry peers.
Industry RankSector Rank
ROA -124.09%
ROE N/A
ROIC N/A
ROA(3y)-142.32%
ROA(5y)-90.32%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ORGS Yearly ROA, ROE, ROICORGS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 1K 2K 3K

1.3 Margins

  • ORGS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ORGS Yearly Profit, Operating, Gross MarginsORGS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 0 -2K -4K -6K -8K -10K

0

2. ORGS Health Analysis

2.1 Basic Checks

  • ORGS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, ORGS has more shares outstanding
  • ORGS has a worse debt/assets ratio than last year.
ORGS Yearly Shares OutstandingORGS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M
ORGS Yearly Total Debt VS Total AssetsORGS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

2.2 Solvency

  • Based on the Altman-Z score of -12.18, we must say that ORGS is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -12.18, ORGS is doing worse than 79.93% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -12.18
ROIC/WACCN/A
WACC7.32%
ORGS Yearly LT Debt VS Equity VS FCFORGS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M -40M -60M

2.3 Liquidity

  • A Current Ratio of 0.07 indicates that ORGS may have some problems paying its short term obligations.
  • ORGS's Current ratio of 0.07 is on the low side compared to the rest of the industry. ORGS is outperformed by 98.76% of its industry peers.
  • A Quick Ratio of 0.07 indicates that ORGS may have some problems paying its short term obligations.
  • ORGS's Quick ratio of 0.07 is on the low side compared to the rest of the industry. ORGS is outperformed by 98.76% of its industry peers.
Industry RankSector Rank
Current Ratio 0.07
Quick Ratio 0.07
ORGS Yearly Current Assets VS Current LiabilitesORGS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

0

3. ORGS Growth Analysis

3.1 Past

  • ORGS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -125.83%.
  • The Revenue for ORGS has decreased by -98.14% in the past year. This is quite bad
  • The Revenue for ORGS have been decreasing by -50.95% on average. This is quite bad
EPS 1Y (TTM)-125.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-52.75%
Revenue 1Y (TTM)-98.14%
Revenue growth 3Y-58.93%
Revenue growth 5Y-50.95%
Sales Q2Q%-96.47%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y190.48%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year39.76%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ORGS Yearly Revenue VS EstimatesORGS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
ORGS Yearly EPS VS EstimatesORGS Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 0 0.5 -0.5 -1 -1.5

4

4. ORGS Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ORGS. In the last year negative earnings were reported.
  • ORGS is valuated cheaply with a Price/Forward Earnings ratio of 3.39.
  • 99.29% of the companies in the same industry are more expensive than ORGS, based on the Price/Forward Earnings ratio.
  • The average S&P500 Price/Forward Earnings ratio is at 22.19. ORGS is valued rather cheaply when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 3.39
ORGS Price Earnings VS Forward Price EarningsORGS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ORGS Per share dataORGS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3 -4 -5

4.3 Compensation for Growth

  • ORGS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. ORGS Dividend Analysis

5.1 Amount

  • No dividends for ORGS!.
Industry RankSector Rank
Dividend Yield N/A

ORGS Fundamentals: All Metrics, Ratios and Statistics

ORGENESIS INC

NASDAQ:ORGS (10/18/2024, 8:00:02 PM)

After market: 2.25 +0.14 (+6.64%)

2.11

-1.13 (-34.84%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-13
Earnings (Next)11-11
Inst Owners3.18%
Inst Owner Change0%
Ins Owners790.6%
Ins Owner Change0%
Market Cap10.06M
Revenue(TTM)662.00K
Net Income(TTM)-37.94M
Analysts82.86
Price Target6.12 (190.05%)
Short Float %0.14%
Short Ratio0.03
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-98.66%
Min Revenue beat(2)-98.85%
Max Revenue beat(2)-98.46%
Revenue beat(4)0
Avg Revenue beat(4)-98.92%
Min Revenue beat(4)-99.2%
Max Revenue beat(4)-98.46%
Revenue beat(8)2
Avg Revenue beat(8)-49.23%
Revenue beat(12)4
Avg Revenue beat(12)-34.26%
Revenue beat(16)6
Avg Revenue beat(16)-8.82%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 3.39
P/S 15.2
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.17
EYN/A
EPS(NY)0.62
Fwd EY29.49%
FCF(TTM)-2.63
FCFYN/A
OCF(TTM)-2.52
OCFYN/A
SpS0.14
BVpS-3.25
TBVpS-5.33
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -124.09%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-142.32%
ROA(5y)-90.32%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 34.15%
Cap/Sales 75.68%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.07
Quick Ratio 0.07
Altman-Z -12.18
F-Score2
WACC7.32%
ROIC/WACCN/A
Cap/Depr(3y)394.92%
Cap/Depr(5y)321.88%
Cap/Sales(3y)150.7%
Cap/Sales(5y)156.63%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-125.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-52.75%
EPS Next Y190.48%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-98.14%
Revenue growth 3Y-58.93%
Revenue growth 5Y-50.95%
Sales Q2Q%-96.47%
Revenue Next Year39.76%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-231.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y59.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y39.92%
OCF growth 3YN/A
OCF growth 5YN/A

ORGENESIS INC / ORGS Fundamental Analysis FAQ

What is the ChartMill fundamental rating of ORGENESIS INC (ORGS) stock?

ChartMill assigns a fundamental rating of 1 / 10 to ORGS.


What is the valuation status of ORGENESIS INC (ORGS) stock?

ChartMill assigns a valuation rating of 4 / 10 to ORGENESIS INC (ORGS). This can be considered as Fairly Valued.


Can you provide the profitability details for ORGENESIS INC?

ORGENESIS INC (ORGS) has a profitability rating of 0 / 10.


What is the earnings growth outlook for ORGENESIS INC?

The Earnings per Share (EPS) of ORGENESIS INC (ORGS) is expected to grow by 190.48% in the next year.